Compound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma

EY Kim, EN Cho, HS Park, JY Hong, S Lim… - Cancer biology & …, 2016 - Taylor & Francis
… actionable oncogenic mutations. This study shows that the compound EGFR mutation is
common in lung adenocarcinoma and imparts a new meaning of compound EGFR mutation. …

[HTML][HTML] Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence

I Attili, A Passaro, P Pisapia, U Malapelle… - Current Oncology, 2022 - mdpi.com
… the issue of the distribution of compound EGFR mutations. For this purpose, according to …
main categories of compound EGFR mutations: combined common EGFR mutations (exon 21 p.…

Clinicopathological characteristics of lung adenocarcinoma with compound EGFR mutations

T Hayashi, S Kohsaka, K Takamochi, K Hara… - Human Pathology, 2020 - Elsevier
… with compound EGFR mutations. We compared compound EGFR mutations with
common or uncommon single-mutation cases. Our study expands the comprehension of the …

A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer

HY Tu, EE Ke, JJ Yang, YL Sun, HH Yan, MY Zheng… - Lung Cancer, 2017 - Elsevier
EGFR mutations and their sensitivity to EGFR-TKIs. Favorable responses were observed in
patients with G719X and compound L858R mutations, … of compound EGFR mutations in this …

The in cis compound EGFR mutations in Chinese advanced non-small cell lung cancer patients

M Li, CZ Zhou, JJ Yang, S Lu, D Zheng… - Cancer Biology & …, 2019 - Taylor & Francis
… cis compound EGFR mutation and single EGFR L858R. We randomly selected 23 patients
from our screened cohort harboring single EGFR … with in cis compound EGFR mutation. The …

Uncommon single and compound EGFR mutations: Clinical outcomes of a heterogeneous subgroup of NSCLC

S Rossi, P Damiano, L Toschi, G Finocchiaro… - Current Problems in …, 2022 - Elsevier
… uncommon EGFR mutations (single or compound mutation). Patients were treated with EGFR
Median OS resulted longer in the compound mutation group when compared to single rare …

[HTML][HTML] Recent advances on the role of EGFR tyrosine kinase inhibitors in the management of NSCLC with uncommon, non exon 20 insertions, EGFR mutations

A Passaro, T Mok, S Peters, S Popat, MJ Ahn… - Journal of Thoracic …, 2021 - Elsevier
… against major uncommon EGFR mutations including compound mutations, but excluding …
EGFR mutations. Moving forward, it will be important to include uncommon EGFR mutations in …

[HTML][HTML] Afatinib for the treatment of NSCLC harboring uncommon EGFR mutations: a database of 693 cases

JCH Yang, M Schuler, S Popat, S Miura… - Journal of Thoracic …, 2020 - Elsevier
… Afatinib has clinical activity in NSCLC against major uncommon and compound EGFR
mutations. It also has broad activity against other uncommon EGFR mutations and some exon 20 …

[HTML][HTML] Successful treatment of lung adenocarcinoma complicated with a rare compound EGFR mutation L833V/H835L using aumolertinib: a case report and …

L Li, S Huang, L Qin, N Yan, S Shen, X Li - Frontiers in Pharmacology, 2023 - frontiersin.org
… This case report, for the first time, presented a patient with rare compound EGFR mutations
… features: the patient harbored rare compound EGFR mutations of L833V/H835L, which were …

[HTML][HTML] Rare mutation-dominant compound EGFR-positive NSCLC is associated with enriched kinase domain-resided variants of uncertain significance and poor …

W Zhao, A Song, Y Xu, Q Wu, C Liu, JC Yin, Q Ou… - BMC medicine, 2023 - Springer
… the difference in EGFR mutational frequency between patients with single EGFR
mutation and those with compound EGFR mutations, we categorized compound mutation-positive …